Clinical Trials on NSCLC, Non Small Cell Lung Cancer in Hungary

Total 266 results

Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Spain, United States, Brazil, Chile, Czechia, France, Hungary, Israel
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)

Ukraine, United Kingdom, United States, Bulgaria, Belgium, Germany, Hungary, Austria, Italy, Israel, Lithuania, Romania, Slovenia
AbbVie (prior sponsor, Abbott)

Completed

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

NSCLC | Lung Cancer | Non-Small-Cell Lung Cancer

United States, Czech Republic, Greece, Hungary, Netherlands, Slovakia
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
Genzyme, a Sanofi Company

Completed

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

United States, Czech Republic, Hungary
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Elevation Oncology
Merrimack Pharmaceuticals

Terminated

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC (SHERLOC)

Adenocarcinoma | Non-Small Cell Lung Cancer | NSCLC | Heregulin

Spain, Canada, United States, Germany, Hungary, France
Transgene
Bristol-Myers Squibb

Completed

A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer Metastatic

Hungary, France, United States, Belgium
Central European Cooperative Oncology Group

Terminated

Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC

Non-Small Cell Lung Cancer

Austria, Hungary, Poland
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

Non - Small Cell Lung Cancer NSCLC

United States, France, Germany, Italy, United Kingdom, Belgium, Poland, Romania, Taiwan, Thailand, Canada, Korea, Republic of, Czechia, Hungary, Japan, Russian Federation, Hong Kong, Spain, Netherlands, Greece, Australia, Serbia, Bu... and more
UCB Pharma

Completed

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Carcinoma | Non-Squamous Non-Small-Cell Lung Cancer

Poland, Russian Federation, Hungary
Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Squamous Non-Small Cell Lung Cancer

Spain, Hungary, Serbia
AstraZeneca

Active, not recruiting

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Non Small Cell Lung Carcinoma NSCLC

Poland, Taiwan, Thailand, Vietnam, United States, Korea, Republic of, Hungary, Russian Federation, Turkey, China, Australia, Netherlands
Innate Pharma

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Non Small Cell Lung Cancer

France, United States, Greece, Hungary, Poland
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (NSCLC)

Non-small Cell Lung Cancer

United States, Hungary, Poland, Russian Federation
AstraZeneca

Active, not recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Non-Small-Cell Lung Carcinoma NSCLC

United States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland
Peregrine Pharmaceuticals

Completed

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small-Cell Lung Carcinoma | Non-Small-Cell Lung Cancer Stage IIIB | Non-Small-Cell Lung Cancer Stage IV | Non-Small-Cell Lung Cancer Metastatic

United States, Australia, Belgium, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Romania, Russian Federation, Spain, Taiwan, Ukraine
Human Genome Sciences Inc.

Completed

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Germany, Hungary, Romania
Hoffmann-La Roche

Completed

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Spain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
MedImmune LLC

Terminated

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Canada, Japan, Poland, Germany, Hungary, France
Pfizer

Terminated

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Non-small Cell Lung Cancer | Urothelial Cancer

Spain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
Prestige Biopharma Limited

Active, not recruiting

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Lung Cancer | Non-small Cell Lung Cancer

India, Hungary, Georgia, Philippines, Belarus, Bulgaria, Croatia, Greece, Latvia, Malaysia, Poland, Russian Federation, Serbia, Slovakia, Thailand, Turkey, Ukraine
AstraZeneca

Approved for marketing

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Non Small Cell Lung Cancer | Cancer of the Head and Neck

Poland, Germany, Hungary, United Kingdom
Incyte Corporation
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

Metastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung Cancer

China, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
Mirati Therapeutics Inc.

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
Synta Pharmaceuticals Corp.

Terminated

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-Small-Cell Lung Adenocarcinoma

United States, France, Spain, Netherlands, Czech Republic, Serbia, Romania, Germany, Belgium, Italy, Hungary, United Kingdom, Canada, Poland, Bosnia and Herzegovina, Austria, Slovenia, Croatia, Russian Federation, Ukraine
Eli Lilly and Company

Completed

A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer Stage IV

United States, Italy, Spain, Australia, France, Germany, Hungary, Korea, Republic of, Poland, Romania, Russian Federation, Taiwan, Ukraine
Spectrum Pharmaceuticals, Inc

Completed

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Non-small Cell Lung Cancer

United States, Czechia, India, Brazil, Argentina, Hungary
NovaRx Corporation

Completed

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

Lung Neoplasm | Carcinoma Non-small Cell Lung Cancer Stage IIIA | Carcinoma Non-small Cell Lung Cancer Stage IIIB | Carcinoma Non-small Cell Lung Cancer Stage IV

United States, Hungary, United Kingdom, Netherlands, Canada, India, Poland, Serbia
Genentech, Inc.

Completed

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Non-Squamous Non-Small Cell Lung Cancer

Australia, United States, Hungary, France, Germany, Czech Republic, Poland
AstraZeneca

Completed

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Non Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, Canada, Brazil, Hungary, Peru, Czechia, Bulgaria, Mexico
Infinity Pharmaceuticals, Inc.

Completed

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Hungary, Taiwan, Korea, Republic of, Russian Federation, Romania
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)

Non-Squamous Cell Non-small Cell Lung Cancer

United States, Germany, Hong Kong, Spain, Australia, Mexico, Austria, France, Singapore, Switzerland, Canada, Poland, Argentina, Brazil, Chile, Czechia, Hungary, Italy, Norway, Peru, Romania, Russian Federation
NovoCure GmbH

Active, not recruiting

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NSCLC | Nonsmall Cell Lung Cancer

United States, Poland, Hong Kong, China, Spain, Serbia, Croatia, France, Canada, Netherlands, Austria, Belgium, Bulgaria, Czechia, Germany, Hungary, Italy, Switzerland
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

Non-small Cell Lung Cancer

United States, New Zealand, Australia, Costa Rica, Taiwan, Argentina, France, Chile, Hungary, Spain, Greece, Poland, Canada, Lithuania, Norway, Italy
Threshold Pharmaceuticals
EMD Serono

Terminated

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Germany, Spain, Poland, Greece, Czechia, Hungary, Italy, Romania, Russian Federation
AstraZeneca
Parexel

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)

Non-small Cell Lung Cancer

Hungary, United States, Italy, Belgium, Spain, France, Korea, Republic of, Taiwan, Turkey, Ireland, Portugal, Canada
Eisai Inc.

Completed

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Canada, United States, United Kingdom, Australia, Israel, Russian Federation, Czech Republic, France, Greece, Hungary, Poland
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, China, Romania, Netherlands, Hong Kong, Austria, Belgium, Czechia, Hungary, Portugal, Greece, Germany, Ireland, Switze... and more
mAbxience Research S.L.

Completed

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (STELLA)

Non-small Cell Lung Cancer

Philippines, Hungary, Chile, Mexico, Spain, Serbia, Malaysia, Brazil, Bulgaria, Georgia, Greece, India, Lebanon, Oman, Russian Federation, Thailand, Turkey, Ukraine
Eli Lilly and Company
University of Colorado, Denver; Quintiles, Inc.; PPD; Parexel; Laboratory Corporation... and other collaborators

Completed

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin (INSPIRE)

Non Small Cell Lung Cancer

Belgium, Brazil, Russian Federation, United Kingdom, Australia, Germany, Hungary, Italy, Romania, United States, Austria, Canada, Croatia, France, Greece, Poland, Portugal, Slovakia, South Africa, Spain
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Non-small Cell Lung Cancer

United States, Spain, Korea, Republic of, Taiwan, Germany, Italy, Japan, France, Hungary, Netherlands
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Squamous Cell Non-small Cell Lung Cancer

United States, France, Chile, Australia, Netherlands, Argentina, Austria, Canada, Czechia, Germany, Hungary, Ireland, Italy, Mexico, Norway, Peru, Poland, Romania, Russian Federation, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer (BASALT-1)

Non-small Cell Lung Cancer

France, Italy, United Kingdom, Hungary, Belgium, Canada, Spain, Germany, Singapore, Netherlands, Thailand, United States, Turkey, Argentina, Brazil, Hong Kong, Japan, Taiwan

Clinical Trials on NSCLC, Non Small Cell Lung Cancer in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations